Silvia Bio

Galatea Bio, founded in 2021 in Miami, Florida, operates a biobank and provides genetic testing services focused on improving diagnostic testing and accelerating drug discovery for diverse and underserved populations.

Network Bio is a Palo Alto, California biotechnology company founded in 2022 that builds disease-specific AI models from human biological data. Its vertically integrated platform combines a biological research network that sources, links and structures tissue, blood and longitudinal clinical outcomes from leading U.S. academic medical centers (Mass General Brigham, University of Pennsylvania, Duke University, University of Colorado Anschutz and UCSF, spanning 500,000+ patients across oncology, immunology, metabolic and cardiovascular disease) into AI-ready datasets, with a bio-native AI architecture purpose-built to learn from multimodal biological data, overcome technical confounders and batch effects, and generate interpretable representations of disease biology that generalize across diseases, tissues and modalities.

Reliant AI, founded in 2023 and headquartered in Montreal, Canada and Berlin, Germany, uses generative AI to help biopharmaceutical companies organize and analyze large volumes of complex data for use cases such as clinical trials and scientific publications.

Dash Bio is a bioanalysis company founded in 2024 in Boston that applies automation and AI to accelerate drug development.

Arsenale Bioyards, founded in 2022 in Milan, Italy, combines advanced bioreactors with AI-driven software to optimize fermentation processes in biomanufacturing, aiming to reduce precision fermentation costs by up to 90% and accelerate the adoption of sustainable alternatives.

Pepper Bio, founded in 2018 in Massachusetts, USA, analyzes multi-layered biological data—including DNA, RNA, proteomic, and phosphoproteomic data—to discover novel drug candidates.